Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

(2020) Raffaele Ornello et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study

(2020) Bianca Raffaelli et al.   Frontiers in Neurology

Guidelines for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults

(2020) Hans-Christoph Diener et al.   CEPHALALGIA

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

(2020) Armin Scheffler et al.   JOURNAL OF HEADACHE AND PAIN

Predicting erenumab adverse events with single-cell genomics

(2020) Angeliki Vgontzas et al.   LANCET

One-year sustained efficacy of erenumab in episodic migraine

(2020) Peter J. Goadsby et al.   NEUROLOGY

Effect of Fremanezumab on Quality of Life and Productivity in Patients With Chronic Migraine

(2020) Richard B. Lipton et al.   NEUROLOGY

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

(2020) Wim M Mulleners et al.   LANCET NEUROLOGY

CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications

(2019) David W Dodick   CEPHALALGIA

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

(2019) Michel D Ferrari et al.   LANCET

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults

(2018) Cristina Tassorelli et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

(2018) Uwe Reuter et al.   LANCET

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design

(2017) Daniel Serrano et al.   JOURNAL OF HEADACHE AND PAIN

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nocebo in headache

(2016) Dimos D. Mitsikostas   CURRENT OPINION IN NEUROLOGY

Detoxification in medication-overuse headache, a retrospective controlled follow-up study: Does care by a headache nurse lead to cure?

(2015) JA Pijpers et al.   CEPHALALGIA

Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine

(2014) Regina Rendas-Baum et al.   Health and Quality of Life Outcomes